Earnings Feed
Start Free
Home/Filings/4/0001077183-25-000040
4//SEC Filing

Sherman Jeffrey Scott 4

Accession 0001077183-25-000040

CIK 0001077183other
View on SEC.govCompany Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 4:38 PM ET

Size

24.5 KB

Accession

0001077183-25-000040

Insider Transaction Report

Form 4
Period: 2025-02-21
NEOGENOMICS INCNEO
Sherman Jeffrey Scott
Chief Financial Officer
Transactions
  • Tax Payment

    Common Stock

    2025-02-23−4,207→ 137,064 total
  • Exercise/Conversion

    Common Stock

    2025-02-23+15,535→ 141,271 total
  • Award

    Stock Option (Right to Buy)

    2025-02-21+214,900→ 214,900 total
    Exercise: $13.05Exp: 2035-02-21→ Common Stock (214,900 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-23−15,535→ 31,071 total
    Exercise: $0.00→ Common Stock (15,535 underlying)
  • Award

    Restricted Stock Unit

    2025-02-21+126,476→ 126,476 total
    Exercise: $0.00→ Common Stock (126,476 underlying)
Holdings

  • Restricted Stock Unit

    Exercise: $0.00From: 2026-04-13→ Common Stock (59,382 underlying)
    59,382

  • Stock Option (Right to Buy)

    Exercise: $19.65Exp: 2030-05-11→ Common Stock (73,016 underlying)
    73,016

  • Performance Stock Unit

    Exercise: $0.00From: 2026-05-11→ Common Stock (39,016 underlying)
    39,016

  • Stock Option (Right to Buy)

    Exercise: $16.45Exp: 2034-02-23→ Common Stock (77,913 underlying)
    77,913

  • Stock Option (Right to Buy)

    Exercise: $11.62Exp: 2029-12-05→ Common Stock (249,169 underlying)
    249,169

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (26,011 underlying)
    26,011

  • Performance Stock Unit

    Exercise: $0.00From: 2027-02-23→ Common Stock (46,606 underlying)
    46,606
Footnotes (14)
  • [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
  • [F10]On May 11, 2023, Mr. Sherman was granted 73,016 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  • [F11]On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F12]On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
  • [F13]On February 23, 2024, Mr. Sherman was granted 77,913 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  • [F14]On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuantto the performance criteriais 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading periodat the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company
  • [F2]This balance includes 1,982 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt from Section 16b-3.
  • [F3]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
  • [F4]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
  • [F5]On February 21, 2025, Mr. Sherman was granted 214,900 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  • [F6]On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F7]Once vested, the shares of common stock are not subject to expiration.
  • [F8]On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F9]On December 5, 2022, Mr. Sherman was granted 249,169 stock options. These awards vest ratably over four years with the first tranche vesting on December 7, 2023.

Documents

1 file

Issuer

NEOGENOMICS INC

CIK 0001077183

→
Entity typeother

Related Parties

1
  • filerCIK 0001463145

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:38 PM ET
Size
24.5 KB
View on SEC.gov